{"title":"Formulation and evaluation of Lamivudinefloating tablets usingCarbopol & Eudragit S 100","authors":"K. C, Jothimanivannan C, G. M, Praveen Kumar M","doi":"10.54037/wjps.2022.100304","DOIUrl":null,"url":null,"abstract":"Lamivudinecomes underclass II drugs according to BCS classification. It is poorly water-soluble drug. It has maximum solubility in pH 1.2 and therefore it will be beneficial to retain the drug in stomach for longer period of time for better absorption. Hence, it was found necessary to develop a gastric retentive dosage form containing Lamivudinein order to increase the gastric residence time to enhance its absorption and they’re by its oral bioavailability. Also, the slow release of the drug in stomach may avoid the stomach pain associated with immediate release of the drug. The ultimate aim was to design, develop and optimize the floating tablets containing Lamivudinein order to increase its gastric retention time for enhancing absorption in stomach as well as to produce a controlled release of the drug for a longer time using polymers such as Carbopol, and EudragitS100.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"147 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of Pharmacy and pharmaceutical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54037/wjps.2022.100304","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lamivudinecomes underclass II drugs according to BCS classification. It is poorly water-soluble drug. It has maximum solubility in pH 1.2 and therefore it will be beneficial to retain the drug in stomach for longer period of time for better absorption. Hence, it was found necessary to develop a gastric retentive dosage form containing Lamivudinein order to increase the gastric residence time to enhance its absorption and they’re by its oral bioavailability. Also, the slow release of the drug in stomach may avoid the stomach pain associated with immediate release of the drug. The ultimate aim was to design, develop and optimize the floating tablets containing Lamivudinein order to increase its gastric retention time for enhancing absorption in stomach as well as to produce a controlled release of the drug for a longer time using polymers such as Carbopol, and EudragitS100.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
